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Abstract: Secondary (or functional) mitral regurgitation (SMR) occurs frequently in chronic heart failure
(HF) with reduced left ventricular (LV) ejection fraction, resulting from LV remodelling that prevents
coaptation of the valve leaflets. Secondary mitral regurgitation contributes to progression of the symp-
toms and signs of HF and confers worse prognosis. The management of HF patients with SMR is complex
and requires timely referral to a multidisciplinary Heart Team. Optimization of pharmacological and de-
vice therapy according to guideline recommendations is crucial. Further management requires careful
clinical and imaging assessment, addressing the anatomical and functional features of the mitral valve
and left ventricle, overall HF status, and relevant comorbidities. Evidence concerning surgical correction
of SMR is sparse and it is doubtful whether this approach improves prognosis. Transcatheter repair has
emerged as a promising alternative, but the conflicting results of current randomized trials require careful
interpretation. This collaborative position statement, developed by four key associations of the Euro-
pean Society of Cardiology-the Heart Failure Association (HFA), European Association of Percutaneous
Cardiovascular Interventions (EAPCI), European Association of Cardiovascular Imaging (EACVI), and
European Heart Rhythm Association (EHRA)-presents an updated practical approach to the evaluation
and management of patients with HF and SMR based upon a Heart Team approach.
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Secondary (or functional) mitral regurgitation (SMR) occurs frequently in chronic heart failure (HF) with reduced left ventricular (LV) ejec-
tion fraction, resulting from LV remodelling that prevents coaptation of the valve leaflets. Secondary mitral regurgitation contributes to
progression of the symptoms and signs of HF and confers worse prognosis. The management of HF patients with SMR is complex and
requires timely referral to a multidisciplinary Heart Team. Optimization of pharmacological and device therapy according to guideline rec-
ommendations is crucial. Further management requires careful clinical and imaging assessment, addressing the anatomical and functional
features of the mitral valve and left ventricle, overall HF status, and relevant comorbidities. Evidence concerning surgical correction of
SMR is sparse and it is doubtful whether this approach improves prognosis. Transcatheter repair has emerged as a promising alternative,
but the conflicting results of current randomized trials require careful interpretation. This collaborative position statement, developed by
four key associations of the European Society of Cardiology—the Heart Failure Association (HFA), European Association of Percutaneous
Cardiovascular Interventions (EAPCI), European Association of Cardiovascular Imaging (EACVI), and European Heart Rhythm Association
(EHRA)—presents an updated practical approach to the evaluation and management of patients with HF and SMR based upon a Heart
Team approach.
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Moderate or severe secondary (also known as functional) mitral re-
gurgitation (SMR) accompanies heart failure (HF) in about one-third
of patients1 and contributes to clinical deterioration, progression of
the syndrome, and adverse outcomes.2–5 Secondary mitral regurgita-
tion results from left ventricular (LV) remodelling as a consequence
of ischaemic or non-ischaemic myocardial disease that leads to
reduced coaptation of normal mitral valve leaflets via several mecha-
nisms.6 Since SMR is principally a disease of the left ventricle and not
of the valve itself, current treatment strategies target the underlying
LV disorder. However, SMR exaggerates LV remodelling by increas-
ing volume load and mechanical correction has been proposed along-
side guideline-directed medical therapy (GDMT) to improve
symptoms and prognosis.
The interventional management of patients with HF and SMR is
challenging. In contrast to primary (including degenerative) mitral re-
gurgitation (MR), the outcomes of surgical mitral valve repair, either
alone or combined with coronary artery bypass grafting (CABG), are
of questionable benefit.7–9 Transcatheter techniques for the correc-
tion of SMR have broadened the spectrum of patients who may
benefit from mitral valve intervention, although current European
Society of Cardiology (ESC) guidelines for the management of both
HF and valvular heart disease (VHD) indicate the need for further
clinical research in this area.10,11 The recently published COAPT12
and MitraClip Device for Severe Functional/Secondary Mitral
Regurgitation (MITRA-FR)13 randomized controlled trials have
addressed this deficit but their conflicting results have generated con-
siderable discussion and require careful interpretation.
This position statement, developed in collaboration by the ESC
Heart Failure Association (HFA), European Association of
Cardiovascular Imaging (EACVI), European Heart Rhythm
Association (EHRA), and European Association of Percutaneous
Cardiovascular Interventions (EAPCI), proposes an updated practical
approach to the management of patients with HF and SMR based on
a multidisciplinary Heart Team approach.We outline the current evi-
dence (and its limitations), discuss open issues that need to be
addressed by future research, and stress the importance of appropri-
ate referral and selection of patients for transcatheter mitral valve
intervention alongside guideline-recommended medical and device
therapies.
Pathophysiology
The pathophysiology of SMR is complex (Figure 1), reflecting imbal-
ance between valve closing and leaflet tethering forces, and the dy-
namic impact of factors affecting LV preload and afterload in patients
with LV remodelling due to ischaemic or non-ischaemic myocardial
disease.6,15–18
Progressive SMR is a marker of poor prognosis in patients with
chronic HF4,19 and the transition from LV disease ‘marker’ to HF
‘contributor’ is critical in determining the need for valve intervention.
The concept of ‘proportionate’ and ‘disproportionate’ MR,20 based
upon a modelled relationship between LV end-diastolic volume and
effective regurgitant orifice area (EROA), and its disruption in
patients with ventricular dyssynchrony or papillary muscle dysfunc-
tion, has been proposed to guide the mode of treatment and predict
the impact of transcatheter intervention. Although attractive from a
pathophysiological point of view, this theoretical model overlooks
the need to assess the severity of MR using an integrated multi-
parametric approach (and, in particular, fails to consider the frequent-
ly elliptical regurgitant orifice in SMR) and has not been validated to
date.
Secondary mitral regurgitation may also arise as a consequence of
left atrial enlargement and mitral annular dilatation/flattening in
patients with longstanding atrial fibrillation (AF), where left ventricu-
lar ejection fraction (LVEF) is often normal and LV dilatation less pro-
nounced. So-called ‘atrial’21,22 MR may also contribute to SMR in
patients with HF and AF. This pathophysiological distinction is im-
portant since treatment options differ.
Epidemiology and prognosis
Moderate or severe MR is present in about one-third of HF patients.1
Early studies indicated that MR is an independent predictor of clinical
HF and major cardiac events following acute myocardial infarction or
in patients with LV dysfunction.23,24 More contemporary data
confirm that SMR is associated with adverse clinical outcomes, inde-
pendent of clinical, haemodynamic, echocardiographic, and neuro-
hormonal confounders. In a cohort of 576 HF patients with reduced
LV ejection fraction (HFrEF) on optimal medical therapy, severe SMR
was associated with mortality in intermediate-severity HF New York
Heart Association (NYHA) class II/III, LVEF 30–40% and N-terminal
pro brain natriuretic peptide (NT-proBNP) 871–2360 pg/mL], but
not in those with more advanced disease.4
Clinical and imaging assessment
Initial evaluation of patients with HF and SMR should include:
• History and physical examination (to define functional, haemo-
dynamic, and volume status, and HF severity).
• Electrocardiogram (to demonstrate baseline rhythm and QRS
duration).
• Laboratory measurements (haemoglobin, renal function, and natri-
uretic peptides),
• Evaluation of LV function (including the presence of myocardial
scar/viability),
• Invasive or non-invasive coronary angiography.
Imaging modalities
Transthoracic echocardiography facilitates integrated structural and
functional assessment of the mitral valve, LV, and left atrium (to-
gether with associated valve disease, right ventricular function, and
estimated pulmonary pressure) and is the key initial screening tool
for standardized measurement of LV function and MR severity.11,25
Transoesophageal imaging provides more accurate anatomical
evaluation, although the effects of sedation on blood pressure may
alter LV loading conditions and result in underestimation of severity.
Since SMR is a dynamic condition, stress echocardiography allows





























assessment of its role during exercise (and possibly acute HF), as well
as haemodynamic assessment of the interaction betweenMR severity
and LV function,26,27 but its precise role remains unclear. Multi-
detector computed tomography provides detailed anatomical infor-
mation and is valuable in planning specific mitral interventions.28,29
Cardiac magnetic resonance allows precise measurement of LV vol-
ume and ejection fraction, identification of fibrosis or scar, and accur-
ate quantification of MR severity, though its availability and use in
clinical practice are limited.30
Anatomical assessment
Determination of the precise mechanism of MR [using three-
dimensional (3D) transthoracic and transoesophageal echocardiog-
raphy if necessary] is essential to define the optimal treatment strat-
egy. Although several aetiologies may coexist in an individual patient,
the predominant mechanism should be identified to distinguish be-
tween those with primary MR and reduced LV function and those
with true SMR.
Key anatomical features are as follows (Figure 2):
Figure 1 The pathophysiology of secondary mitral regurgitation (SMR). Primary disease of the left ventricular (LV) myocardium or damage sec-
ondary to ischaemic heart disease results in papillary muscle displacement, leaflet tethering, annular remodelling, and dilatation. Compensatory mech-
anisms of adaptive leaflet growth are typically insufficient (and frequently accompanied by maladaptive leaflet thickening and fibrosis),14 resulting in
failure of leaflet coaptation. Dynamic factors affecting LV preload (e.g. hydration status, medication) and afterload (e.g. blood pressure, exercise,
medication) impact on the severity of resulting SMR. Progressive LV dilatation begets increasing SMR and the resulting increase in regurgitant fraction
(with corresponding reduction in forward flow) impacts negatively on the Frank–Starling curve. Adapted with permission from Mullens and
Martens.15 EMT, epithelial-mesenchymal transition; HF, heart failure; LV, left ventricle; LA, left atrium; MR, mitral regurgitation; PM, papillary muscle;
TGF-b, transforming growth factor beta.














































































































































































• Mitral valve: degree of leaflet tethering, tenting area, coaptation
depth, jet location (central vs. commissural), presence or absence
of leaflet calcification, angle between the posterior leaflet and an-
nular plane, posterior leaflet length, and valve area (ideally >5 mm
and >_4 cm2 for edge-to-edge repair, respectively).
• Left ventricle: end-diastolic and end-systolic diameters and volumes,
LVEF, LV dyssynchrony, sphericity index (long/short LV axis),
inter-papillary muscle distance, regional wall motion abnormalities.
• Other structures: left atrial volume, left atrial appendage (to exclude
thrombus), right ventricular dimensions and function, concomitant
tricuspid regurgitation, estimated pulmonary artery pressure.
Echocardiographic assessment of
secondary mitral regurgitation severity
Severity of SMR should be assessed using an integrated multi-
parametric approach.31,32 Two-dimensional transthoracic echocardi-
ography has specific limitations in the setting of SMR and 3D imaging
should be used whenever feasible. Importantly, SMR is a dynamic
phenomenon and severity may vary significantly according to loading
conditions33—assessment should be undertaken in stable clinical
conditions (controlled blood pressure, optimal medical therapy), and
interpreted cautiously in decompensated patients (fluid overload,
inotropic support).
Definitions vary in Europe and the USA (Table 1)11,34,35 and this
discordance is of pivotal importance when considering the differing
inclusion criteria of clinical trials. European guidelines define severe
SMR as an EROA >_20 mm2 or regurgitant volume >_30 mL, based
upon adverse outcomes in observational studies using these specific
thresholds.23,26,36 However, quantitative assessment is highly
operator-dependent with limited reproducibility, inaccurate in the
presence of an elliptical regurgitant orifice (observed frequently in
SMR) or multiple jets, and often overlooked in everyday clinical prac-
tice. To mitigate the risk of error, multiple parameters should be
assessed [vena contracta, pulmonary vein systolic flow reversal, prox-
imal isovelocity surface area (PISA) radius, and the subsequently
derived EROA and regurgitant volume],11,35 including 3D imaging




Heart failure is characterized by multiple cardiovascular and non-
cardiovascular comorbidities and management of individual patients
is frequently complex. Pharmacological, surgical, device, and trans-
catheter treatment options (and criteria for their optimal use) are
constantly evolving.39 Multidisciplinary management of HF is strongly
recommended in the ESC guidelines (Class IC)10,40 to achieve the
best mode, sequence, and timing of treatment tailored to the needs
of an individual patient. Although unsupported by a robust evidence
base, the advantages of Heart Team management and decision-
making have already been demonstrated in patients with complex
coronary and VHD.11,41 In the HF setting, the Heart Team should in-
clude an HF specialist, a cardiovascular imaging specialist, a cardiac
electrophysiologist, an interventional cardiologist with expertise in
transcatheter mitral valve intervention, and a cardiac surgeon with
experience in mitral valve surgery. According to local institutional cir-
cumstances, this team should meet regularly, in particular to discuss
patients with complex clinical and anatomical characteristics.
Pharmacological therapy
Optimization of GDMT is the first essential step in management of
symptomatic moderate or severe SMR.10Neurohormonal inhibitors,
including angiotensin-converting enzyme inhibitors (ACEi), angioten-
sin receptor blockers (ARB), beta-blockers, and mineralocorticoid
receptor antagonists are mandatory in patients with HFrEF
unless contraindicated or intolerable, and should be titrated to
the guideline-directed dose (or maximum tolerated). These agents
attenuate LV dysfunction and remodelling,42,43 while some studies
show that ACEi and beta-blockers may reduce SMR whilst
improving LV geometry and function (although evidence remains
inconclusive).44,45
Further pharmacological options in patients who remain symp-
tomatic include ivabradine (if sinus rhythm is maintained with heart
rate >_70 b.p.m. despite beta-blockade, or if beta-blockers are not tol-
erated) and replacement of ACEI or ARB with sacubitril/valsartan.10
In the PRIME study enrolling patients with HF and SMR, sacubitril/val-
sartan induced a significant reduction of EROA and regurgitant vol-
ume at 1 year follow-up on top of standard medical therapy (without
inducing hypotension or other adverse events).46 Diuretics, nitrates,
and hydralazine also reduce LV preload and afterload and are associ-
ated with symptomatic improvement in patients with SMR.18,47
Oral anticoagulation is essential in patients with AF and SMR.
Alternative therapeutic approaches focused on rhythm and rate con-
trol (including catheter ablation) may reduce the severity of ‘atrial’
MR22,48 but are beyond the scope of this position statement.
Cardiac resynchronization therapy
Intraventricular dyssynchrony may itself precipitate SMR via various
mechanisms.49 Although no prospective randomized clinical trials
have investigated cardiac resynchronization therapy (CRT) in the set-
ting of severe MR, CRT improves global LV function, attenuates LV
remodelling, and reduces papillary muscle dyssynchrony in patients
with QRS prolongation, thereby reducing SMR by increasing mitral
valve closing forces and reducing leaflet tethering both at rest and
during exercise.
Large randomized trials have confirmed short- and long-term re-
duction of MR (assumed to be of secondary origin in the majority of
patients) following CRT implantation50 as a result of reverse remod-
elling,51,52 although the magnitude of this reduction is modest (20–
35% using different quantification methods). Short-term reduction in
MR after CRT implantation predicts a favourable clinical response,53
whereas persistent MR is associated with reduced survival.54,55
Coronary revascularization
Although the merits of surgical revascularization in HF have been
well investigated,56 there are only limited data demonstrating a lower
incidence of cardiovascular adverse events compared with medical
therapy in patients with SMR.57–59 Following isolated CABG, MR
improves in about 50% of patients.60,61
Data concerning the effects of percutaneous coronary interven-
tion in SMR are limited. Reduction of MR was observed in about one-
third of the patients in one small study and linked to better survival.62














































The extent and distribution of myocardial perfusion defects appear
to predict clinical response.63
Surgery
Current ESC/EACTS guidelines provide consensus recommenda-
tions for mitral valve surgery in patients with (i) severe SMR and
LVEF >30% who are undergoing CABG (Class I Level C), (ii) symp-
tomatic severe SMR and LVEF <30% with evidence of myocardial via-
bility and revascularization options (Class IIa Level C), and (iii)
symptomatic severe SMR and LVEF >30% but unsuitable for revascu-
larization (Class IIb Level C).11However, it is important to emphasize
that these recommendations were made before the availability of ro-
bust data supporting the potential benefits of transcatheter valve re-
pair techniques.
The evidence supporting surgical intervention for SMR remains
weak. Mitral annuloplasty, the most commonly used technique for
surgical mitral valve repair, reduces MR, improves symptoms, and
results in reverse LV remodelling in the short term.64 It remains un-
clear whether these outcomes are durable or reduce mortality7,8 al-
though low rates of recurrent MR (28%) have been recently
reported at 10-year follow-up in a single-centre study.65 In a random-
ized controlled trial, additional surgical treatment of moderate SMR
(EROA 0.2–0.39 cm2) had no beneficial clinical effect in patients
undergoing surgical revascularization at 2-year follow-up.9 Besides re-
pair, chordal sparing MV replacement presents a further surgical op-
tion. In a randomized study comparing mitral valve repair and chordal
sparing mitral valve replacement in patients with severe SMR, there
was no significant difference in 2-year mortality (19.0% vs. 23.2%;
P=0.39) or rates of LV reverse remodelling.66 Although recurrent
Figure 2 Key echocardiographic data in secondary mitral regurgitation concerning the mitral valve (A, B) and left ventricle (C, D). (A) The tenting
area (highlighted in red) is bound by the anterior and posterior leaflets and the mitral annular plane (white arrow). (B) Coaptation depth represents
the distance from the annular plane of the mitral valve to the leaflet coaptation point (yellow arrow). (C) The LV diameter (red arrow)must bemeas-
ured in end-diastole and end-systole. (D) Sphericity index is the ratio between the measured end-diastolic volume (EDV) and a spherical volume
based on the longitudinal dimension of the left ventricle. Ao, aorta; LA, left atrium; LV, left ventricle; T, tenting area.













































































































MR was more frequent in the repair group (58.8% vs. 3.8%,
P<0.001) resulting in a higher rate of cardiovascular re-
hospitalization (48.3 vs. 32.2 per 100 patient-years, P=0.01), patients
in the repair group without recurrent MR demonstrated significant
reverse remodelling. In the absence of effective surgical approaches
to the ventricular aspect of SMR, novel repair techniques that may re-
duce MR more effectively by combining subannular reconstruction
(e.g. papillary muscle relocation) or leaflet augmentation with stand-
ard annuloplasty require further evaluation.67
Overall, however, isolated valve surgery is rarely performed for
SMR in real-world clinical practice due to the high procedural risk
and inconsistent evidence of clinical benefit.68 Patients with advanced
HF and severe SMR may be better served by cardiac transplantation
or LV assist device implantation (either as destination therapy or a
bridge to transplantation).
Transcatheter mitral valve repair
The 2017 ESC guidelines for the management of VHD provide a
Class IIb Level C recommendation for the use of transcatheter edge-
to-edge repair in patients with SMR and impaired LV function who
remain symptomatic despite optimal medical therapy11 but do not in-
corporate insights from recent randomized controlled trials investi-
gating the role of transcatheter techniques in this patient group.
As a result of large-scale clinical experience (>100 000 patients)
and high levels of patient safety, MitraClip has become the first-line
interventional treatment option for SMR in Europe. Clinical improve-
ment (change of NYHA class, increased 6-min walking distance and
reverse LV remodelling)69–72 and improved survival73–75 have been
reported after transcatheter mitral edge-to-edge repair in several ob-
servational studies. Predictors of poor outcome have also been iden-
tified: advanced HF (NYHA class IV), severe reduction in LVEF
(<30%), very high EROA (>70 mm2), extremely high NT-proBNP
values (>10 000 pg/mL), significant right ventricular dysfunction (tri-
cuspid annular plane systolic excursion <15mm), severe pulmonary
hypertension or tricuspid regurgitation, and the presence of major
comorbidities (such as significant renal dysfunction).71,72,76,77
Two recent randomized controlled trials from France and the
USA/Canada have evaluated the safety and efficacy of MitraClip im-
plantation in patients with symptomatic HF and moderate-severe
SMR despite medical therapy (Table 2).
In the French multicentre Percutaneous Repair with the MITRA-
FR trial,13 304 patients with symptomatic HF (NYHA class II–IV),
LVEF of 15–40% (but no limit of end-systolic dimension), a history of
at least one HF hospitalization within 1 year and severe SMR (defined
as EROA>20mm2 or regurgitant volume >30mL) but unsuitable for
surgery were randomized to undergo MitraClip implantation plus
GDMT or GDMT alone. MitraClip implantation had no impact on
the primary endpoint of all-cause mortality or HF hospitalization at
12months compared with GDMT alone (HR 1.16, 95% CI 0.73–
1.84) and no additional effect on functional status, 6-min walking dis-
tance, quality of life, or LV end-diastolic volumes (although incom-
plete assessment of these secondary outcome measures hampered
meaningful statistical analysis). Recently reported extended observa-
tions showed no change in these findings at 24-month follow-up,
with no impact of MitraClip implantation on all-cause mortality or HF
hospitalization.79
In the Cardiovascular Outcomes Assessment of the MitraClip
Percutaneous Therapy for Heart Failure Patients with Functional
Mitral Regurgitation (COAPT) trial,12 614 patients with symptomatic
HF (NYHA class II, III, or ambulatory IV), LVEF 20–50%, LV end-
systolic diameter <_70mm, at least one HF hospitalization within the
previous year or increased natriuretic peptide levels, with moderate-
to-severe or severe SMR (semi-quantitative grade 3þ or 4þ accord-
ing to integrative assessment based on American Society of
Echocardiography recommendations)35,80 and in whom surgery was
not considered the standard of care were randomized to undergo
MitraClip implantation plus optimal GDMT or optimal GDMT alone.
MitraClip implantation substantially reduced the primary endpoint
(hospitalization for HF, 35.8% vs. 67.9% per patient-year: HR 0.53,
....................................................................................................................................................................................................................
Table 1 Summary of the European and US guideline definitions of severe SMR
2017 ESC guidelines11 2017 ASE guidelines35 2020 AHA/ACC
guidelines34
Semi-quantitative criteria
Vena contracta (mm) >_7 (>8 for biplane) >_7 —
Pulmonary vein Pulmonary vein systolic flow reversal Pulmonary vein systolic flow reversal —
Inflow E-wave dominant >_1.5m/s — —
Other TVI mitral/TVI aortic >1.4 Central large jet > 50% of LA area —
Quantitative criteria Primary Secondary
EROA (mm2) >_40 >_20 >_40
(or 30–39 with 3 other severity criteria
or elliptical orifice)
>_40
PISA radius — — >_1.0 cm at Nyquist 30–40 cm/s —
Regurgitant volume (mL) >_60 >_30 >_60 >_60
Regurgitant fraction (%) — — >_50 >_50
ACC, American College of Cardiology; AHA, American Heart Association; ASE, American Society of Echocardiography; EROA, effective regurgitant orifice area; ESC,
European Society of Cardiology; LA, left atrium; PISA, proximal isovelocity surface area; TVI, time velocity integrals.

















95% CI 0.40–0.70, P<0.001; NNT 3.1, 95% CI 1.9–7.9) and every 1
of 10 pre-specified, statistically powered secondary endpoints
[including 2-year all-cause mortality (29.1% vs. 46.1%: HR 0.62, 95%
CI 0.46–0.82, P<0.001; NNT 5.9, 95% CI 3.9–11.7), the composite
of death and HF re-hospitalization (45.7% vs. 67.9%: HR 0.57, 95% CI
0.45–0.71, P<0.001; NNT 4.5, 95% CI 3.3–7.2), symptomatic status
(NYHA class I/II 72.2% vs. 49.6%; P<0.001), change in quality of life
(Kansas City Cardiomyopathy Questionnaire score þ12.5± 1.8 vs.
-3.6± 1.9 points; HR 16.1, 95% CI 11.0–21.2; P<0.001), and 6-min
walking distance (-2.2± 9.1 vs. -60.2± 9.0 m; HR: 57.9, 95% CI 32.7–
....................................................................................................................................................................................................................
Table 2 Key differences between the COAPTand MITRA-FR trials (modified from Praz et al.78)
MITRA-FR COAPT
Primary endpoint All-cause death and hospitalization
for HF at 12months
All hospitalizations for HF within 24months (including
recurrent events)
Key exclusion criteria
Heart failure severity NYHA class < II NYHA class < II
ACC/AHA stage D HF
Left ventricular dimensions No exclusion criteria LVESD >70 mm
Coronary artery disease CABG or PCI performed
within 1month
Untreated coronary artery disease requiring
revascularization
Right ventricle No exclusion criteria Right-sided HF with moderate or severe right ventricu-
lar dysfunction
Tricuspid valve disease requiring surgery
Pulmonary disease No exclusion criteria COPD with home oxygen therapy or chronic oral ster-
oid use
PAP >70 mmHg unresponsive to vasodilator therapy
Principal baseline characteristics
Number of patients screened 450 1576
Number of patients enrolled (ITT) 304 614
Mean age (years) 70 ± 10 72± 12
Mean LVEF (%) 33 ± 7 31± 10
MR severity (EROA, cm2) 0.31 ± 0.10 0.41± 0.15
<30 mm2 (%) 52% 13%
30–40 mm2 (%) 32% 46%
>40 mm2 16% 41%
Mean indexed LVEDV, mL/m2 135± 35 101± 34
Safety and efficacy endpoints in intervention arm
Complicationsa (%) 14.6 8.5
No implant (%) 9 5
Implantation of multiple clips (%) 54 62
Post-procedural MR grade <_2þ (%) 92 95
MR grade <_2þ at 1 year (%) 83 95
Hospitalization for HF at 1 year (%)
Edge-to-edge repair þ GDMT 49 36
GDMT alone 47 68
Thirty-day mortality (%)
Edge-to-edge repair þ GDMT 3 2
GDMT alone 3 1
One-year mortality (%)
Edge-to-edge repair þ GDMT 24 19
GDMT alone 22 23
Two-year mortality (%)
Edge-to-edge repair þ GDMT 34 29
GDMT alone 35 46
BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; EROA, effective regurgitant orifice area; GDMT, guideline-directed medical treatment; HF, heart
failure; ITT, intention to treat; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; MR, mitral regurgitation; NT-proBNP, N-terminal pro brain
natriuretic peptide; PAP, pulmonary artery pressure.
aDevice implant failure, transfusion, or vascular complication requiring surgery, ASD, cardiogenic shock, cardiac embolism/stroke, tamponade, and urgent cardiac surgery.

























































































83.1, P<0.001), and the need for LV assist device implantation or
heart transplantation during the study period (4.4% vs. 9.5%: HR 0.37,
95% CI 0.17–0.81, P=0.01)]. These benefits were even more pro-
nounced at 3-year follow-up [composite endpoint of death and HF
re-hospitalization 58.8% vs. 88.1%, HR 0.48 (95% CI 0.39–0.59),
P<0.001; NNT 3.4 (95% CI 2.7–4.6)].81 Cost-effectiveness analysis
at 2 years confirmed a higher cost of intervention overall ($73 416 vs.
$38 345, P<0.001; predominantly related to the price of the
MitraClip device) despite the increased cost of follow-up in the
GDMT group ($38 345 vs. $26 654; P=0.018), and acceptable eco-
nomic value based on current US thresholds (incremental cost-
effectiveness ratio $40 361 per life-year gained, $55 600 per quality-
adjusted life-year gained).82
Whilst these two trials appear superficially similar in design, a num-
ber of differences between them may partly explain their diverging
results:
• Patient selection: In MITRA-FR, local investigators determined eligi-
bility, while in COAPT, this was confirmed by a central eligibility
committee.
• Medical therapy: In COAPT, a central eligibility committee directed
up-titration of medical therapy to maximally tolerated doses prior
to randomization. Patients were excluded from the trial if their
symptoms subsided or MR decreased as a consequence.
Subsequent modification of medical treatment was discouraged in
both groups.
Conversely in MITRA-FR, up-titration of medical therapy before
randomization was directed by the local Heart Team and constantly
adapted to clinical circumstances after randomization in both groups,
consistent with real-world practice.
Therefore, use of ACEi and ARB, and intensification of drug treat-
ment (particularly beta-blockers) during follow-up was more fre-
quent in the MitraClip group in COAPT, although the absolute
impact of these differences on outcomes remains uncertain. The use
of sacubitril/valsartan was low in both trials. Overall, these differences
suggest that the COAPT trial enrolled more patients refractory to
current evidence-based medical treatment than MITRA-FR.
• Echocardiographic assessment: Important differences in the severity
of SMR, degree of LV dilatation, and accompanying parameters of
right heart function are summarized in Table 2. Reflecting the
echocardiographic trial inclusion criteria (Figure 3), patients in
COAPT demonstrated greater severity of SMR based upon quan-
titative criteria (EROA 41 ± 15 mm2 vs. 31 ± 10 mm2) and less
LV dilatation (mean indexed LV end-diastolic volume 101 ± 34
mL/m2 vs. 135±35 mL/m2) than those enrolled in MITRA-FR.
Perhaps reflecting greater severity of MR in relation to LV dimen-
sions, patients in COAPT were overall more likely to benefit from
transcatheter edge-to-edge repair in terms of reduced mortality
and need for HF hospitalization20 (although improvements in qual-
ity of life appeared to be independent of these parameters).83
Importantly, no single echocardiographic variable (whether prog-
nostic or not) was able to predict the outcomes observed follow-
ing MitraClip implantation in the COAPT trial.80 In summary,
echocardiographic assessment was undertaken using different
parameters in the two studies—hence, only very limited conclu-
sions can be drawn at this stage and composite assessment of
both datasets by a single independent core laboratory may prove
valuable.
• Technical factors: The results of MITRA-FR and COAPT indicate
that transcatheter mitral edge-to-edge repair using the MitraClip
....................................................................................................................................................................................................................
Table 3 Randomized trials of transcatheter mitral valve repair in patients with heart failure and secondary mitral
regurgitation
Study acronym HF status LV status SMR severity N Intervention Primary
endpoint
Hazard ratio



























































EROA, effective regurgitant orifice area; GDMT, guideline-directed medical therapy; HF, heart failure.; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left
ventricular end-systolic diameter; NPs, natriuretic peptides; NYHA, New York Heart Association class; Rvol, regurgitant volume; SMR, secondary mitral regurgitation.
































































































device is a safe procedure that effectively reduces SMR. However,
procedural differences (particularly the more frequent use of mul-
tiple clips) may explain the better long-term reduction of SMR in
COAPT with impact on overall clinical outcomes (notwithstanding
the different systems for grading MR in the two trials). Arguably,
these differences in technical outcomes are more relevant than
differences in medical therapy and highlight the importance of
achieving the best possible immediate result after MitraClip
implantation.
The fact that differences in clinical characteristics, advanced echo-
cardiographic findings and initial use of medical therapy are likely to
have accounted for the diverging trial outcomes further emphasizes
the critical importance of careful patient selection for transcatheter
mitral valve intervention by a Heart Team (see Executive Summary
section). The ongoing RESHAPE-HF2 trial will randomize 650
(according to the revised plan) patients with symptomatic HF
(NYHA class II, III or ambulatory IV), LVEF 15–45%, a history of at
least one HF hospitalization within the previous year or increased
natriuretic peptide levels, and moderate-severe or severe SMR
(EROA >_30 mm2) to MitraClip implantation plus GDMT or GDMT
alone (Table 3). The primary endpoint is cardiovascular death or re-
current HF hospitalization and results are expected in 2022.
Meanwhile, the MATTERHORN trial (ClinicalTrials.gov,
NCT02371512) is comparing the merits of transcatheter edge-to-
edge repair with surgery in patients at high-surgical risk with LVEF
>_20%. The results of these and future trials, combined with ongoing
analyses of the MITRA-FR and COAPT databases to identify res-
ponders to edge-to-edge repair, are urgently needed to refine algo-
rithms that ensure selection of the right patients by the right clinicians
for transcatheter treatment of SMR with the right device at the right
time (Figure 4).
Futility and end-of-life care
Expensive, high-risk and ultimately futile procedures should be
avoided in patients who are expected to derive little symptomatic
benefit or improvement in quality of life. Examples include those with
very limited life expectancy (<1 year) due to extra-cardiac conditions,
severe right ventricular impairment or pulmonary disease, impaired
mobility as a result of neurological or musculoskeletal disease, or
advanced dementia. Specialist palliative care should be available for
these patients.
Open questions
The findings of the COAPT trial confirm the prognostic and symp-
tomatic impact of SMR in HF patients. Although longer-term follow-
up is essential, the diverging results of MITRA-FR and COAPT place
even greater emphasis on the need for careful selection of patients
for transcatheter repair techniques and identification of improved
imaging parameters (including thresholds of MR severity) that will
predict positive clinical outcomes. A greater relative degree of SMR
in relation to LV dimensions may identify patients who are more like-
ly to benefit from intervention and this concept warrants further in-
vestigation in future studies incorporating sophisticated imaging
techniques (advanced echocardiography—including 3D imaging—
and cardiac magnetic resonance).20 Furthermore, better character-
ization and stratification of the SMR population may allow distinction
between those patients whomay obtain prognostic benefit and those
who will derive symptom relief and reduced need for hospitalization
alone. In practice, this may not be simple—no single echocardio-
graphic variable predicted beneficial outcomes in the COAPT trial80
and patient-level analysis of the MITRA-FR trial failed to identify any
Figure 3 Echocardiographic inclusion criteria in the COAPT trial.79 EROA, effective regurgitant orifice area; LA, left atrium; LVEF, left ventricular
ejection fraction; LVESD, left ventricular end-systolic diameter; MR, mitral regurgitation; PISA, proximal isovelocity surface area; PV, pulmonary vein;
RF, regurgitant fraction; RV, regurgitant volume; sPAHT, systolic pulmonary artery pressure; VC, vena contracta; ve, velocity.












































combination of echocardiographic parameters associated with clinic-
al benefit following intervention (including those with disproportion-
ate MR).84 Sub-studies from the COAPT trial showed that
symptomatic and prognostic improvements were observed irre-
spective of NYHA class, exercise capacity, and the presence of CRT
at baseline.85–87
Transcatheter mitral valve repair for SMR is a rapidly evolving field.
Beyond the MitraClip device, other percutaneous techniques are
now approved for commercial use in Europe: indirect annuloplasty
using the Carillon Mitral Contour System (Cardiac Dimensions,
Kirkland, WA, USA),88 direct annuloplasty using the Cardioband
Mitral System (Edwards Lifesciences, Irvine, CA, USA),89 and edge-
to-edge repair using the PASCAL Mitral Valve Repair System
(Edwards Lifesciences, Irvine, CA, USA).90,91 The Carillon system has
been recently investigated in a randomized sham-controlled study
(REDUCE-FMR) enrolling 120 patients receiving GDMT.88 At
12months, indirect annuloplasty using this system was associated
with a significant 22% fall in MR regurgitant volume (the primary end-
point) accompanied by significant reduction in LV volumes and im-
provement in paired 6-min walking distance and NYHA functional
class. However, the trial was not powered for clinical endpoints and
between-group differences (including the incidence of mortality or
HF re-hospitalization) did not differ significantly.
Since the safety and utility of MitraClip have now been proven in
selected patients, the potential for intervention earlier in the natural
history of the disease to prevent irreversible LV remodelling and sys-
tolic impairment will need to be rigorously evaluated in future stud-
ies. Further research is also needed for specific populations
Figure 4 A practical algorithm for the management of secondary mitral regurgitation. Heart Team: HF specialist, cardiovascular imaging specialist,
interventional cardiologist with expertise in transcatheter mitral valve repair, cardiac electrophysiologist, and cardiac surgeon with experience in mi-
tral valve surgery. CABG, coronary artery bypass grafting; CAD, coronary artery disease; CRT, cardiac resynchronization therapy (with or without
defibrillator); GDMT, guideline-directed medical therapy; HF, heart failure; HTx, heart transplantation; LV, left ventricular; LVAD, left ventricular as-
sist device; MR, mitral regurgitation; PCI, percutaneous coronary intervention; RV, right ventricular; yr, year. *Current studies have established the
safety and effectiveness of the MitraClip for this purpose—ongoing studies will determine whether other edge-to-edge mitral repair devices are as
safe and effective.














































































































































































overlooked in recent studies, including those with advanced HF
(excluded from COAPT) or marked LV dilation and severe SMR
(EROA >_30 mm2, under-represented in MITRA-FR). Integrative
approaches combining the benefits of pharmacological, electro-
physiological, and transcatheter valve interventions and their relative
priority in individual patients will ultimately determine the optimal
management of SMR in HF.
Finally, and perhaps most importantly, timely assessment and man-
agement of SMR remain suboptimal.89 Robust diagnostic criteria, ear-
lier referral for specialist assessment and stricter evidence-based
selection criteria will increase the net benefit of transcatheter valve
and other advanced interventions.92–95 These priorities need to be
addressed urgently alongside improved education and training of the
wider cardiovascular community—only then will outcomes for the
high-risk group of patients with SMR and HF improve significantly.
Conclusions
SMR affects a large proportion of patients with HF and is independ-
ently associated with adverse prognosis. Timely diagnosis is therefore
essential and requires high-quality imaging delivered by trained imag-
ing specialists to appropriately define the severity and mechanism(s)
of MR, and predict the potential response to treatment. Management
is complex and these patients should be referred for timely Heart
Team assessment and management. Medical therapy should be opti-
mized and adjusted meticulously over long-term follow-up in all
patients with SMR and HF, supplemented by CRT according to guide-
line recommendations. The COAPT trial provides robust evidence
supporting the use of transcatheter mitral edge-to-edge repair using
the MitraClip device in patients who remain symptomatic despite
these measures and match the trial inclusion criteria. Given that these
findings were not duplicated in the MITRA-FR trial, however, further
data will be needed to refine optimal patient selection criteria. Heart
Teams may also consider the use of transcatheter mitral edge-to-
edge repair for symptomatic improvement in patients who do not
match these criteria if alternative treatments (including LV assist de-
vice therapy or heart transplantation) are inappropriate or unavail-
able. Whilst international guidelines should be updated to reflect the
findings of the recent randomized trials, further high-quality studies
are required to refine selection criteria, explore indications beyond
the current evidence base, and investigate the role of other trans-
catheter treatment options (annuloplasty, combined repair techni-
ques, valve replacement).
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Executive summary
The Management of Secondary Mitral Regurgitation in
Heart Failure
• Secondary mitral regurgitation (SMR) is a common consequence of
left ventricular remodelling and associated with adverse prognosis.
• Severity of SMR should be assessed by experienced echocardiogra-
phers using an integrated multi-parametric approach.
• Patients with symptomatic heart failure (HF) and moderate or se-
vere SMR should be referred in a timely manner to a multidisciplin-
ary Heart Team, including:
• Heart failure specialist
• Cardiovascular imaging specialist
• Interventional cardiologist with expertise in transcatheter mitral
valve repair
• Cardiac electrophysiologist
• Cardiac surgeon with experience in mitral valve surgery
• The Heart Team should first evaluate and optimize guideline-
directed medical therapy (GDMT) and then consider the respective
roles of device therapy (including cardiac resynchronization therapy,
CRT), transcatheter mitral intervention and surgery (mitral repair,
ventricular assist systems or transplantation), and their order of
implementation.
• Decisions concerning treatments for mitral regurgitation, other than
pharmacological therapy or circulatory support, should ideally be
made in stable patients without fluid overload or the need for ino-
tropic support.
• Surgical treatment of severe SMR should be considered in operable
patients with coronary artery disease requiring surgical
revascularization.
• Transcatheter edge-to-edge repair* is an evidence-based treatment
option in patients with severe SMR who remain symptomatic des-
pite GDMT (including CRT when indicated) and who have been
carefully selected by a multidisciplinary Heart Team.
• Circulatory support devices and cardiac transplantation should be
considered as an alternative in patients with advanced left and/or
right ventricular failure.
• Interventions for mitral regurgitation should be avoided in patients
with life expectancy <1 year due to conditions unrelated to the mi-
tral regurgitation.
*Current studies have established the safety and effectiveness of the MitraClip
for this purpose—ongoing studies will determine whether other edge-to-edge
mitral repair devices are as safe and effective.
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Corrigendum to:Gone with wind: a novel biodegradable occluder for percutaneous closure of patent foramen ovale.
DOI: 10.1093/eurheartj/ehaa807.
In the originally published version of this manuscript, the word ‘arterial septum’ should be corrected as ‘atrial septum‘. This has now been
corrected online.
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